CAR-T therapies, another type of immunotherapy made by reprograming T cells to express chimeric antigen receptors (CARs) in order to bind to the antigens present on the cancer cells are another potential target therapy in GBM, having better BBB penetration and being able to directly destroy glioma cells without the help of the already suppressed immune system, mutant EGFR, interleukin-13 receptor α chain variant 2 (IL13Rα2), and human epidermal growth factor receptor 2 (HER2), which are the most targeted antigens [95]. This evidence concerns the gene ERBB2 and glioblastoma.